

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40 minutes  
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source (CS) field  
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced  
NEWS 5 AUG 24 CA/Caplus enhanced with legal status information for U.S. patents  
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY  
NEWS 7 SEP 11 WPIDS, WPIINDEX, and WPIX now include Japanese FTERM thesaurus

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:10:32 ON 19 OCT 2009

```

=> file registry
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                    ENTRY SESSIONS
FULL ESTIMATED COST                           0.22      0.22

```

FILE 'REGISTRY' ENTERED AT 16:10:45 ON 19 OCT 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 OCT 2009 HIGHEST RN 1188905-91-0  
DICTIONARY FILE UPDATES: 18 OCT 2009 HIGHEST RN 1188905-91-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>


=> s dmxaa  
L1 3 DMXAA

=> d 11 1-3

L1 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 853799-58-3 REGISTRY  
ED Entered STN: 05 Jul 2005  
CN 9H-Xanthen-4-acetic acid, 5,6-dimethyl-9-oxo-, mixt. with  
2-[(2,6-dichlorophenyl)amino]benzeneacetic acid (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN DMXAA-diclofenac mixture  
MF C17 H14 O4 . C14 H11 C12 N O2  
CI MXS  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL


CM 1

CRN 117570-53-3  
CMF C17 H14 O4




CM 2

CRN 15307-86-5  
CMF C14 H11 C12 N O2



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN  
 RN 129095-08-5 REGISTRY  
 ED Entered STN: 31 Aug 1990  
 CN 9H-Xanthen-4-acetic acid, 5,6-dimethyl-9-oxo-, sodium salt (1:1) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 9H-Xanthen-4-acetic acid, 5,6-dimethyl-9-oxo-, sodium salt (9CI)  
 OTHER NAMES:  
 CN DMXXAA sodium salt  
 MF C17 H14 O4 . Na  
 CI COM  
 SR CA  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, IMSPATENTS, IMSRESEARCH, TOXCENTER,  
 USPAT12, USPATFULL  
 (\*File contains numerically searchable property data)  
 CRN (117570-53-3)




● Na

6 REFERENCES IN FILE CA (1907 TO DATE)  
 6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN  
 RN 117570-53-3 REGISTRY  
 ED Entered STN: 18 Nov 1988  
 CN 9H-Xanthen-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)  
 OTHER NAMES:  
 CN 5,6-Dimethyl-9-oxo-9H-xanthen-4-ylacetic acid  
 CN 5,6-Dimethylxanthenone-4-acetic acid  
 CN AS 1404  
 CN ASA 404  
 CN DMXXAA  
 CN NSC 640488  
 CN Vadimezan  
 MF C17 H14 O4  
 CI COM  
 SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN\*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CIN, EMBASE, IMPATENTS, IMSRESEARCH, IPA, MEDLINE, PHAR, PROMT, PROUSDDR, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

196 REFERENCES IN FILE CA (1907 TO DATE)  
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
196 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s gemcitabine  
1.2 11 GEMCITABINE

=> file caplus  
COST IN U.S. DOLLARS  
SINCE FILE ENTRY SESSION  
17.33 17.55  
FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 16:11:09 ON 19 OCT 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Oct 2009 VOL 151 ISS 17  
FILE LAST UPDATED: 18 Oct 2009 (20091018/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at: [www.cas.org/casinfo](http://www.cas.org/casinfo)

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate identification of the substances.

substance identification.

=> s 11

L3 197 L1

=> s 12

L4 5378 L2

=> s 11 and 12

197 L1

5378 L2

L5 6 L1 AND L2

=> dup rem 15

PROCESSING COMPLETED FOR L5

L6 6 DUP REM L5 (0 DUPLICATES REMOVED)

=> d 16 1-6 ibib abs

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:739059 CAPLUS

DOCUMENT NUMBER: 151:86657

TITLE: Combinations of therapeutic agents comprising vascular disrupting agent such as 5,6-dimethylxanthenone-4-acetic acid, for treating cancer

INVENTOR(S): Evans, Dean Brent; Jacques, Christian J.

PATENT ASSIGNEE(S): Novartis A.-G., Switz.

SOURCE: PCT Int. Appl., 57pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009076170	A2	20090618	WO 2008-US85535	20081204
WO 2009076170	A3	20090730		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA


PRIORITY APPLN. INFO.: US 2007-13335P P 20071213

AB The invention relates to a combination comprising vascular disrupting agent (VDA), such as 5,6-dimethylxanthenone-4-acetic acid or a pharmaceutically acceptable salt, ester or prodrug thereof; and one or more pharmaceutically active agents; pharmaceutical compns. comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a com. package comprising said combination. Thus, the effects of 5,6-dimethylxanthenone-4-acetic acid (Compound A), trastuzumab and paclitaxel are evaluated for their antitumor activity using the BT-474 human breast ductal carcinoma xenograft model; the data shows that Compound A at 20 mg/kg given i.v. on days 1, 5 and 9 is

able to produce inhibition of tumor growth; paclitaxel combined with trastuzumab is also active resulting in a combination effect; when Compound A at 20 mg/kg is combined with paclitaxel and trastuzumab, increased activity is apparent resulting in tumor regressions; using the Clark Combination Index method, synergy is indicated; the tolerability of the triple combinations is no worse than that observed when Compound A is dosed alone.

16 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:1250046 CAPLUS  
 DOCUMENT NUMBER: 149:448110  
 TITLE: Preparation of Iso CA-4 and analogs as potent  
       cytotoxic agents and inhibitors of polymerization of  
       tubulin  
 INVENTOR(S): Alami, Mouad; Brion, Jean-Daniel; Provot, Olivier;  
                   Peyrat, Jean-Francois; Messaoudi, Samir; Hamze,  
                   Abdallah; Giraud, Anne; Bignon, Jerome; Bakala,  
                   Joanna; Liu, Jian-Miao  
 PATENT ASSIGNEE(S): Centre National De La Recherche Scientifique, Fr.  
 SOURCE: PCT Int. Appl., 78pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008122620	A1	20081016	WO 2008-EP54118	20080404
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2914640	A1	20081010	FR 2007-54280	20070404
PRIORITY APPLN. INFO.:			FR 2007-54280	A 20070404



AB Isocombretastatin A-4 and analogs I [R1, R2, R3 = methoxy (possibly substituted by one or more fluorine atoms); R5 = R6 = hydrogen or fluorine; A = ring chosen from (un)substituted aryls and heteroaryls]

The process for the preparation of I comprises: (a) reaction of acetophenone derivative II with an organometallic compound, A-M [M = alkali metal or earth alkaline metal substituted with a halogen]; and (b) reaction of the resulting phenylethanol derivative III with an acid to form I. Thus, Iso-CA-4 [I; A = C6H3OH-3-OMe-4, R1 = R2 = R3 = OMe, R4 = R5 = R6 = H (IV)] was prepared from 3,4,5-trimethoxyacetophenone (II; R1 = R2 = R3 = OMe, R4 = R5 = R6 = H) via reaction in PhMe with tert-butyl(5-lithio-2-methoxyphenoxy)dimethylsilane [prepared from tert-butyl(5-iodo-2-methoxyphenoxy)dimethylsilane via lithiation with Me3CLi in hexane], dehydration of III with p-toluenesulfonic acid in CH2Cl2, and desilylation with K2CO3 in MeOH. The cytotoxic activity of IV was determined [IC50 = 2-4 nM vs. HCT116; IC50 = 5 nM vs. K562 cells; IC50 = 2 nM vs. B16F10 cells; IC50 = 8 nM vs. U87 cells; IC50 = 8 nM vs. A549 cells; IC50 = 4.5 nM vs. M435 cells; IC50 = 4 nM vs. M231 cells; IC50 = 2.2  $\mu$ M vs tubulin polymerization].

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:473431 CAPLUS  
 DOCUMENT NUMBER: 148:463206  
 TITLE: oncolytic viruses and antiangiogenic agents in the treatment of cancer  
 INVENTOR(S): Karrasch, Matthias; Mescheder, Axel  
 PATENT ASSIGNEE(S): Medigene AG, Germany  
 SOURCE: PCT Int. Appl., 69pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008043576	A1	20080417	WO 2007-EP8930	20071015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2073823	A1	20090701	EP 2007-819001	20071015
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: US 2006-851598P P 20061013  
 WO 2007-EP8930 W 20071015  
 AB The invention relates to a combination of at least one oncolytic virus and at least one antiangiogenic agent and to the use of this combination in tumor therapy. Intraarterial infusions of oncolytic virus NV1020 to a patient with progressive metastatic colorectal adenocarcinoma followed by CPT-11 plus cetuximab resulted in stabilization of the disease at 6 mo post treatment.  
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:984120 CAPLUS  
 DOCUMENT NUMBER: 143:279360  
 TITLE: Methods of detecting CD133 antigen (AC133) expression level and use as biomarker for human cancer diagnosis and therapy monitor  
 INVENTOR(S): Penning, Maarten Tjerk; Van den Broek, Sebastiaan; Johannes Jacobus; Voest, Emile Eugene; Beerepoet, Laurens Victor; Mehra, Niven  
 PATENT ASSIGNEE(S): Primagene Holding B. V., Neth.; UMC Utrecht Holding B. V.  
 SOURCE: PCT Int. Appl., 55 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1571225	A1	20050907	EP 2004-75686	20040302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CA 2558604	A1	20050909	CA 2005-2558604	20050302
EP 1725679	A1	20061129	EP 2005-710924	20050302
EP 1725679	B1	20090603		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
AT 432997	T	20090615	AT 2005-710924	20050302
US 20070077578	A1	20070405	US 2006-514345	20060831
US 20090098563	A1	20090416	US 2008-284203	20080919
PRIORITY APPLN. INFO.:				
			EP 2004-75686	A 20040302
			US 2004-549450P	P 20040302
			EP 2005-710924	A 20050302
			WO 2005-NL155	W 20050302
			US 2006-514345	B1 20060831

AB This invention provides methods of detecting CD133 antigen (AC133) expression level and use as a biomarker for human cancer diagnosis and therapy monitor. Blood anal. including number of circulating endothelial cells and expression levels of human genes AC133 (CD133), EST032 and U1A evaluated by NASBA anal., were determined prior to and during chemotherapy using drugs such as angiostatin or PrimMed01, gemcitabine, and cisplatin, for a wide range of human tumor types. A use of a nucleic acid mol. comprising at least part of a sequence of AC133 or an analog thereof for monitoring a treatment of an individual suffering from a disease is also provided, as well as a diagnostic kit comprising such nucleic acid mol.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:975665 CAPLUS  
 DOCUMENT NUMBER: 143:264929  
 TITLE: Methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases  
 INVENTOR(S): Penning, Maarten Tjerk; Beerepoot, Laurens Victor; Van Den Broek, Sebastiaan Johannes Jacobus; Mehra, Niven; Voest, Emile Eugene  
 PATENT ASSIGNEE(S): Primagen Holding B.V., Neth.; UMC Utrecht Holding B.V.  
 SOURCE: Eur. Pat. Appl., 28 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1571225	A1	20050907	EP 2004-75686	20040302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CA 2558604	A1	20050909	CA 2005-2558604	20050302
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W: AE, AG, AL, AM, AT, UA, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JE, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1725679	A1	20061129	EP 2005-710924	20050302
EP 1725679	B1	20090603		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
AT 432997	T	20090615	AT 2005-710924	20050302
PRIORITY APPLN. INFO.:			EP 2004-75686	A 20040302
			US 2004-549450P	P 20040302
			WO 2005-NL155	W 20050302

AB The invention provides methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases. AC133 antigen mRNA may be quantitated by PCR, RT-PCR, NASBA, SDA, TMA, bDNA or rolling circle amplification. Diseases include cancer and heart disease, high blood pressure, ischemia, stroke, psoriasis, Crohn's disease, rheumatoid arthritis, endometriosis, atherosclerosis, obesity, diabetes mellitus, diabetic retinopathy, macular degeneration, Alzheimer's disease, Peutz Jeghet's syndrome, multiple sclerosis, systemic lupus erythematosus, Wegener's granulomatosis, vasculitis, sickle cell disease, thalassemia and angina.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
 (1 CITINGS)  
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:202462 CAPLUS

DOCUMENT NUMBER: 138:226761

TITLE: Synergistic anticancer combinations containing

5,6-dimethylxanthone-4-acetic acid  
INVENTOR(S) : Wilson, William Robert; Siim, Bronwyn Gae  
PATENT ASSIGNEE(S) : Cancer Research Technology Limited, UK  
SOURCE: PCT Int. Appl., 31 pp.

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020259	A2	20030313	WO 2002-GB4025	20020903
WO 2003020259	A3	20030417		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2458459	A1	20030313	CA 2002-2458459	20020903
AU 2002324143	A1	20030318	AU 2002-324143	20020903
AU 2002324143	B2	20070913		
EP 1423105	A2	20040602	EP 2002-758562	20020903
EP 1423105	B1	20081203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012258	A	20041019	BR 2002-12258	20020903
JP 2005509599	T	20050414	JP 2003-524567	20020903
CN 1708296	A	20051214	CN 2002-817257	20020903
NZ 531045	A	20060831	NZ 2002-531045	20020903
EP 1759694	A2	20070307	EP 2006-77049	20020903
EP 1759694	A3	20090218		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI				
NZ 546573	A	20070531	NZ 2002-546573	20020903
CN 1994287	A	20070711	CN 2006-10151393	20020903
NZ 554093	A	20080731	NZ 2002-554093	20020903
AT 415963	T	20081215	AT 2002-758562	20020903
ES 2321283	T3	20090604	ES 2002-758562	20020903
NO 2004000591	A	20040430	NO 2004-591	20040210
ZA 2004001078	A	20050415	ZA 2004-1078	20040210
US 20040204480	A1	20041014	US 2004-790943	20040302
MX 2004002004	A	20050217	MX 2004-2004	20040302
IN 2004CN00684	A	20060113	IN 2004-CNG84	20040402
AU 2007202083	A1	20070531	AU 2007-202083	20070509
AU 2007202083	B2	20090820		
US 20080070847	A1	20080320	US 2007-830650	20070730
US 20080070848	A1	20080320	US 2007-830659	20070730
US 20080070886	A1	20080320	US 2007-830668	20070730
US 20080070849	A1	20080320	US 2007-830677	20070730
IN 2008CN02044	A	20090911	IN 2008-CN2044	20080424
AU 20090202760	A1	20090730	AU 2009-202760	20090708
PRIORITY APPLN. INFO.:				
		GB 2001-21285	A 20010903	
		AU 2002-324143	A3 20020903	
		CN 2002-817257	A3 20020903	
		EP 2002-758562	A3 20020903	
		WO 2002-GB4025	W 20020903	

US 2004-790943 A1 20040302  
IN 2004-CNG84 A3 20040402  
AU 2007-202083 A3 20070509

AB The present invention relates to synergistic combinations of the 5,6-dimethylxanthone-4-acetic acid (DMXAA) and a compound selected from platinum compds., Vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have antitumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compds. containing the combinations. The antitumor activity and host toxicity of DMXAA/cytotoxic drug combinations was assessed by varying the dose of chemotherapeutic drug up to the toxicity limit, with co-administration of a fixed DMXAA dose (80  $\mu$ mol/kg, ca. 80% of MTD), and evaluating subsequent tumor growth delay. Of the 7 drugs investigated, 4 (doxorubicin, 5-fluorouracil, cyclophosphamide and cisplatin) had appreciable activity against this tumor as indicated by dose-response relationships providing significant slopes by linear regression, and highly significant growth delays of 10 days at their MTDs.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file medline embase biosis  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 19.00 36.55  
  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL  
ENTRY SESSION  
CA SUBSCRIBER PRICE -4.92 -4.92

FILE 'MEDLINE' ENTERED AT 16:12:08 ON 19 OCT 2009

FILE 'EMBASE' ENTERED AT 16:12:08 ON 19 OCT 2009  
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:12:08 ON 19 OCT 2009  
Copyright (c) 2009 The Thomson Corporation

=> s ll<chem>

SmartSELECT INITIATED  
New TRANSFER and ANALYZE Commands Now Available  
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 3.21 39.76  
  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL  
ENTRY SESSION  
CA SUBSCRIBER PRICE 0.00 -4.92

FILE 'REGISTRY' ENTERED AT 16:12:14 ON 19 OCT 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

SET SMARTSELECT ON  
SET COMMAND COMPLETED

SEL L1 1- CHEM  
L7 SEL L1 1- CHEM : 12 TERMS

SET SMARTSELECT OFF  
SET COMMAND COMPLETED

COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
15.08 54.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL  
CA SUBSCRIBER PRICE ENTRY SESSION  
0.00 -4.92

FILE 'MEDLINE' ENTERED AT 16:12:14 ON 19 OCT 2009

FILE 'EMBASE' ENTERED AT 16:12:14 ON 19 OCT 2009  
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:12:14 ON 19 OCT 2009  
Copyright (c) 2009 The Thomson Corporation

S L7  
L8 661 L7

=> s 18 and (?cancer? or ?tumor? or ?tumour? or ?neoplasm?)  
L9 630 L8 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)

=> s 19 and pd<20020903  
2 FILES SEARCHED...  
L10 255 L9 AND PD<20020903

=> s 110 and (potentiat? or ?enhanc? or ?increas?)  
L11 161 L10 AND (POTENTIAT? OR ?ENHANC? OR ?INCREAS?)

=> s 111 and (gemcitabine or antimetabolite)  
L12 0 L11 AND (GEMCITABINE OR ANTIMETABOLITE)

=> d his

(FILE 'HOME' ENTERED AT 16:10:32 ON 19 OCT 2009)

FILE 'REGISTRY' ENTERED AT 16:10:45 ON 19 OCT 2009  
L1 3 S DMXAA  
L2 11 S GEMCITABINE

FILE 'CAPLUS' ENTERED AT 16:11:09 ON 19 OCT 2009  
L3 197 S L1  
L4 5378 S L2  
L5 6 S L1 AND L2  
L6 6 DUP REM L5 (0 DUPLICATES REMOVED)

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:12:08 ON 19 OCT 2009

FILE 'REGISTRY' ENTERED AT 16:12:14 ON 19 OCT 2009  
SET SMARTSELECT ON  
L7 SEL L1 1- CHEM : 12 TERMS  
SET SMARTSELECT OFF

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:12:14 ON 19 OCT 2009  
L8 661 S L7  
L9 630 S L8 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)  
L10 255 S L9 AND PD<20020903  
L11 161 S L10 AND (POTENTIAT? OR ?ENHANC? OR ?INCREAS?)  
L12 0 S L11 AND (GEMCITABINE OR ANTIMETABOLITE)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

	SINCE FILE	TOTAL
	ENTRY	SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	3.61	58.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-4.92

STN INTERNATIONAL LOGOFF AT 16:14:36 ON 19 OCT 2009